The market for prothrombin complex concentrates demand is anticipated to be worth US$ 772.0 million in 2023 and US$ 1.2 billion in 2033. The United Kingdom, the United States, China, and India are expected to emerge as major producers as the market for prothrombin complex concentrates is predicted to grow at a steady CAGR of 4.1%.
The global Prothrombin Complex Concentrates market is set to witness robust growth in the coming decade, with a projected valuation of US$ 1.2 billion by 2033. According to market analysts, the market is estimated to be valued at US$ 772.0 million in 2023, demonstrating a steady rise.
Prothrombin Complex Concentrates (PCC) are critical therapeutic agents used to treat bleeding disorders, primarily in patients with deficiencies in clotting factors. They play a vital role in managing hemorrhages caused by congenital coagulation factor deficiencies, liver diseases, and vitamin K antagonists. The increasing prevalence of bleeding disorders, coupled with rising surgical procedures and trauma cases, is driving the demand for PCC.
Key factors contributing to the anticipated growth of the Prothrombin Complex Concentrates market include advancements in the healthcare infrastructure, a rise in awareness about bleeding disorders, and the development of innovative PCC formulations. Additionally, a growing geriatric population and the increasing incidence of hemophilia and other clotting disorders are expected to fuel market expansion.
Identify key trends, drivers, and challenges in the market, which will help vendors improve their strategies to stay ahead of their competitors. View our PDF Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-7032
A new study by the company titled ‘Prothrombin Complex Concentrates Market: Global Industry Analysis 2013–2017 and Opportunity Assessment 2018–2028’, has listed out the key points being considered by the companies operating in the prothrombin complex concentrates market to emerge and stay sustainably profitable in the long run. The North America prothrombin complex concentrates market is projected to expand at a CAGR of 3.5% over the forecast period. North America and Western Europe are expected to be dominant markets for prothrombin complex concentrates, as most of the manufacturing facilities of prothrombin complex concentrates are located in these regions. However, the increasing demand for optimized & sustainable healthcare in countries of Asia Pacific, such as China and India, and of Middle-East is expected to fuel the growth of the prothrombin complex concentrates market.
The report finds the players operating in the market are laying emphasis on improving treatment options for patients with hemophilia B. Treatment with prothrombin complex concentrates is an economical option for warfarin reversal. It is has been observed that the treatment with prothrombin complex concentrates is the most economical option as it minimizes the hospital stay and laboratory costs. Direct healthcare costs including drug and hospital costs in Europe are approximately US$ 400,000 for prothrombin complex concentrates, whereas for warfarin withdrawal therapy, it was approximated US$ 1,200,000.
Manufacturers tend to depend on plasma as a primary precursor to manufacture prothrombin complex concentrates, and in the past, they relied on third-party sources for plasma. Manufacturers are now opening their own plasma collection banks to reduce dependence on third-party sources. This trend has been observed to have grown since 2013. The key players operating in the market, such as CSL Behring & Shire, have scaled up their focus on depending on their own sources for plasma.
